[Form 4] Cadrenal Therapeutics, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Cadrenal Therapeutics insider Form 4 summary: Quang Pham, CEO, Chairman, director and reported 10% owner of Cadrenal Therapeutics, Inc. (CVKD), reported sales of company common stock on 09/24/2025 and 09/25/2025. On 09/24/2025 he sold 2,581 shares at $13.99 each, leaving 210,723 shares directly owned after that transaction. On 09/25/2025 he sold 6,790 shares in multiple transactions with a weighted average price of $14.09, leaving 203,933 shares directly owned after those sales. Mr. Pham also has indirect ownership of 200,000 shares held by The PVBQ Living Trust; he is Trustee with sole voting and disposition power and the trust’s sole beneficiary is his child. The filing was signed by an attorney-in-fact on 09/26/2025.

Positive

• Timely disclosure of insider transactions through a filed Form 4
• Substantial retained exposure via indirect ownership of 200,000 shares in The PVBQ Living Trust
• Clear governance detail showing Trustee status and sole voting/disposition power

Negative

• Insider sales by the CEO (2,581 and 6,790 shares) reduced direct holdings, which may prompt investor questions
• Form does not state total outstanding shares, so transaction materiality and percentage ownership change cannot be assessed from this filing alone

Insights

Securities Analyst

TL;DR: CEO sold modest blocks of stock over two days while retaining substantial direct and indirect holdings, indicating partial liquidity rather than full exit.

The reported sales on 09/24 and 09/25 reduced Mr. Pham’s direct stake from 210,723 to 203,933 shares after the two transaction dates shown in the form. The amounts sold (2,581 and 6,790 shares) and the prices ($13.99 and a $14.09 weighted average) are clearly disclosed. Materiality depends on total outstanding shares, which is not provided, so market impact cannot be determined from this filing alone. Continued indirect ownership of 200,000 shares via The PVBQ Living Trust signals retained economic exposure.

Corporate Governance Expert

TL;DR: Insider sales by the CEO were disclosed and the filing documents trustee control of a family trust holding additional shares.

The Form 4 shows timely disclosure of insider transactions and clarifies the reporting person’s roles: CEO, Chairman, director and 10% owner. It also documents that Mr. Pham has sole voting and disposition power over The PVBQ Living Trust’s 200,000 shares and that the trust’s beneficiary is his child. These governance details are important for understanding control and potential related-party considerations but do not indicate violations or other governance breaches in this filing.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Pham Quang X

(Last) (First) (Middle)

C/O CADRENAL THERAPEUTICS, INC., 822

A1A NORTH, SUITE 306

(Street)

PONTE VEDRA FL 32082

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cadrenal Therapeutics, Inc. [ CVKD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and Chairman

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/24/2025		S		2,581	D	$13.99(1)	210,723	D
Common Stock	09/25/2025		S		6,790	D	$14.09(2)	203,933	D
Common Stock								200,000	I	The PVBQ Living Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions, at a price of $13.99 for each transaction.

2. Represents shares of the Issuer's common stock sold by the Reporting Person in multiple transactions at prices ranging from $13.99 through $14.14, inclusive, having a weighted average price as shown in column 4 of $14.09. The Reporting Person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

3. Quang Pham is the Trustee of The PVBQ Living Trust and has sole voting and disposition power with respect to the shares owned by The PVBQ Trust, of which Mr. Pham's child is the sole beneficiary.

	/s/ Matthew K. Szot, Attorney-in-fact	09/26/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did CVKD CEO Quang Pham report on the Form 4?

The Form 4 reports sales of 2,581 shares on 09/24/2025 at $13.99 each and sales totaling 6,790 shares on 09/25/2025 at a weighted average price of $14.09.

How many CVKD shares does Quang Pham own after these transactions?

The filing shows 203,933 shares directly owned following the 09/25/2025 transactions and 200,000 shares indirectly owned through The PVBQ Living Trust.

What is The PVBQ Living Trust and who controls it?

The filing states Quang Pham is the Trustee with sole voting and disposition power over The PVBQ Living Trust, whose sole beneficiary is his child.

When was the Form 4 signed and filed?

The signature block shows the form was signed by an attorney-in-fact on 09/26/2025.

Does the Form 4 show the total outstanding shares or percentage ownership?

No. The filing does not disclose total outstanding shares or the percent ownership represented by the reported holdings.